Plain-English translation of NCT07014176 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 4 — The treatment has already been approved. Researchers are tracking how it works in a large number of people over time.
This study is testing a treatment called Amnion-Intermediate-Chorion (AIC)—a specially processed sheet made from donated human placenta tissue—to see if it helps diabetic foot ulcers heal better. Some participants will receive standard wound care only, while others will receive the tissue sheet plus standard care. Researchers want to know whether adding this tissue sheet helps ulcers close faster and more completely.
Many people with diabetes develop foot ulcers that don't heal well with regular wound care, and these wounds can become infected or lead to serious complications. This medication is designed to help the body rebuild skin layers and close these stubborn wounds more effectively.
You likely qualify if…
You likely don't qualify if…
You will be randomly assigned to receive either standard wound care alone or standard care plus the placenta tissue treatment. Either way, you'll have weekly visits for up to 12 weeks where your wound will be cleaned, treated, and monitored. You must also agree to use a special offloading device (like a special shoe or boot) to protect your foot during the trial. The study ends when your ulcer closes or after 12 weeks, whichever comes first.
AI-generated summary from trial data · Jun 22, 2026 · Not medical advice
United States